We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+30.23%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$365M
Cap. Flow
+$51.2M
Cap. Flow %
2.74%
Top 10 Hldgs %
59.4%
Holding
57
New
5
Increased
14
Reduced
4
Closed
8

Top Buys

1
ETNB
89bio
ETNB
+$18.4M
2
GPCR icon
Structure Therapeutics
GPCR
+$18.2M
3
APLS
Apellis Pharmaceuticals
APLS
+$13.8M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$12.8M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.1M

Top Sells

1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$36.6M
2
ELVN icon
Enliven Therapeutics
ELVN
+$14.3M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.71M
4
REPL icon
Replimune Group
REPL
+$6.62M
5
PRTA icon
Prothena Corp
PRTA
+$6.17M

Sector Composition

1 Healthcare 99.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
51
Enliven Therapeutics
ELVN
$3.84B
– –
-1,050,483
Closed -$14.3M
PASG icon
52
Passage Bio
PASG
$15.6M
– –
-87,911
Closed -$1.16M
PRTA icon
53
Prothena Corp
PRTA
$456M
– –
-127,900
Closed -$6.17M
REPL icon
54
Replimune Group
REPL
$854M
– –
-386,762
Closed -$6.62M
SNDX icon
55
Syndax Pharmaceuticals
SNDX
$2.04B
– –
-600,000
Closed -$8.71M
SNDX icon
56
PUT
Syndax Pharmaceuticals
SNDX
$2.04B
– –
-600,000
Closed -$1.57M
STRO icon
57
Sutro Biopharma
STRO
$390M
– –
-78,000
Closed -$2.71M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2023 Portfolio in Review

As of Q4 2023, Frazier Life Sciences Management held 57 positions worth $1.87B, up 24% from $1.51B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Frazier Life Sciences Management's Q4 2023 filing shows 5 new, 14 increased, 4 reduced and 8 closed positions. Its largest new stake was 89bio: 2,000,000 shares worth $22.3M. The largest sale was Crinetics Pharmaceuticals, an estimated $36.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q4 2023 buy was 89bio: 2,000,000 shares worth $22.3M.
  • Frazier Life Sciences Management added most to Apellis Pharmaceuticals in Q4 2023, an estimated $13.8M increase.
  • Frazier Life Sciences Management's biggest Q4 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $36.6M.
  • Frazier Life Sciences Management fully exited Enliven Therapeutics in Q4 2023, selling an estimated $14.3M.
  • Frazier Life Sciences Management's ten largest holdings make up 59% of its $1.87B portfolio in Q4 2023.
  • Frazier Life Sciences Management opened 5 new positions and closed 8 in Q4 2023.
  • Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.87B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.